Luteal Support and Risk of Ovarian Hyperstimulation in Assisted Reproduction (A Review)

Luteal Support and Risk of Ovarian Hyperstimulation in Assisted Reproduction (A Review)

Background. Gonadotropin-releasing hormone agonist as an ovulation trigger effectively reduces the ovarian hyperstimulation risk in in vitro fertilisation protocols, at the same time requiring an effective luteal phase support in embryo transfer cycles.Objectives. A review of modern approaches to lu...

Full description

Bibliographic Details
Main Authors:	V. A. Krutova, A. A. Baklakova
Format:	Article
Language:	Russian
Published:	Ministry of Healthcare of the Russian Federation. “Kuban State Medical University” 2020-12-01
Series:	Кубанский научный медицинский вестник
Subjects:	ovarian hyperstimulation syndrome in vitro fertilisation gonadotropin-releasing hormone agonist luteal support
Online Access:	https://ksma.elpub.ru/jour/article/view/2237

Similar Items

Ovarian hyperstimulation syndrome following the use of GnRH agonist trigger of final oocyte maturation and freeze-all strategy: A case report and review of the literature
by: Dalia Khalife, et al.
Published: (2022-01-01)

Effect of luteal phase support gonadotropin-releasing hormone agonist on the endometrial receptivity and outcomes of in vitro fertilization programs
by: E M Savelyeva, et al.
Published: (2016-06-01)

Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis
by: Nalini Mahajan, et al.
Published: (2015-01-01)

Luteal Coasting and Individualization of Human Chorionic Gonadotropin Dose after Gonadotropin-Releasing Hormone Agonist Triggering for Final Oocyte Maturation—A Retrospective Proof-of-Concept Study
by: Barbara Lawrenz, et al.
Published: (2018-02-01)

Single-Dose Versus Multiple-Dose GnRH Agonist for Luteal-Phase Support in Women Undergoing IVF/ICSI Cycles: A Network Meta-Analysis of Randomized Controlled Trials
by: Yang Liu, et al.
Published: (2022-03-01)

Hematocrit as a simple method to predict and manage ovarian hyperstimulation syndrome in assisted reproduction
by: Taswin Kaur, et al.
Published: (2015-01-01)

Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study
by: Rena Yamazaki, et al.
Published: (2020-01-01)

Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome – a prospective randomized double-blind clinical trial
by: L. L. Engmann, et al.
Published: (2019-01-01)

Pregnancy outcome in long- versus short-acting gonadotropin-releasing hormone agonist cycles in participants with normal ovarian reserve: An RCT
by: Roya Kabodmehri, et al.
Published: (2023-10-01)

Severe Ovarian Hyperstimulation Syndrome despite low dose stimulation in Polycystic Ovarian Syndrome
by: Robin George Manappallil, et al.
Published: (2019-05-01)

The effect of luteinizing hormone changes in GnRH antagonist protocol on the outcome of controlled ovarian hyperstimulation and embryo transfer
by: Jing-Shuang Zhou, et al.
Published: (2023-08-01)

The best execution of the DuoStim strategy (double stimulation in the follicular and luteal phase of the same ovarian cycle) in patients who are poor ovarian responders
by: Yanqun Luo, et al.
Published: (2020-10-01)

Ovarian Cyst Formation Following Gonadotropin-Releasing Hormone-Agonist Administration Decreases the Oocyte Quality in IVF Cycles
by: Muammer Doğan, et al.
Published: (2012-06-01)

Effect of luteal-phase GnRH agonist on frozen-thawed embryo transfer during artificial cycles: a randomised clinical pilot study
by: Yanghong Liu, et al.
Published: (2023-06-01)

Luteal-phase support in assisted reproductive technology: An ongoing challenge
by: Saeideh Dashti, et al.
Published: (2021-09-01)

اثربخشی آنتاگونیست هورمون آزاد کننده‌ی گونادوتروپین (ستروتاید) در مقایسه با کابرگولین در پیش‌گیری و درمان سندرم تحریک بیش از حد تخمدان
by: Elham Naghshineh, et al.
Published: (2021-02-01)

RISK FACTORS AND CRITERIA FOR PREDICTION OF OVARIAN HYPERSTIMULATION SYNDROME
by: N. V. Protopopova, et al.
Published: (2012-05-01)

Comparison of gonadotropin-releasing hormone agonist with GnRH antagonist in polycystic ovary syndrome patients undergoing in vitro fertilization cycle: Retrospective analysis from a tertiary center and review of literature
by: Neeta Singh, et al.
Published: (2014-01-01)

Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus
by: Raoul Orvieto, et al.
Published: (2021-05-01)

Prolonged pituitary down-regulation with full-dose of gonadotropin-releasing hormone agonist in different menstrual cycles: a retrospective cohort study
by: Yingfen Ying, et al.
Published: (2019-04-01)

Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells
by: Kuan-Hao Tsui, et al.
Published: (2014-03-01)

Impact of Mid-Luteal Phase GnRH Agonist Administration on Reproductive Outcomes in GnRH Agonist-Triggered Cycles: A Randomized Controlled Trial
by: Abdelhamid Benmachiche, et al.
Published: (2017-06-01)

Investigating Ovulation Induction Outcomes in Patients with Decreased Ovarian Reserve Treated with Double Stimulation during The Follicular and Luteal Phases Compared to The Conventional Antagonist Cycle: A Randomized Clinical Trial
by: Fatemeh Ghahghayi, et al.
Published: (2024-04-01)

Association of Thr307Ala and Asn680Ser of Follicle-Stimulating Hormone Receptor Gene Polymorphisms with Gonadotropin Administration during Controlled Ovarian Hyperstimulation
by: Qing-Xia Meng, et al.
Published: (2018-01-01)

Determinants of the hCG Concentration in the Early Luteal Phase After Final Maturation of Follicles With Bolus Trigger of Recombinant hCG
by: Lan N. Vuong, et al.
Published: (2020-03-01)

Risk Factors and Methods for Predicting Ovarian Hyperstimulation Syndrome (OHSS) in the in vitro Fertilization
by: S. P Pakhomov, et al.
Published: (2021-11-01)

A short length of gonadotropin hyperstimulation is sufficient to achieve an optimal IVF outcome in advance-aged women
by: Le Tien Hsu, et al.
Published: (2021-11-01)

ENDOMETRIOSIS AND FERTILITY. KEY MOMENT OF TREATMENT
by: S. A. Gasparyan, et al.
Published: (2016-06-01)

Initiating luteal phase support with sc progesterone based on low serum progesterone on the transfer day in true natural cycle frozen embryo transfers
by: Cem Demirel, et al.
Published: (2023-10-01)

Low-dose hCG as trigger day and 35 hr later have different ovarian hyperstimulation syndrome occurrence in females undergoing In vitro fertilization: An RCT
by: Marzieh Aghahosseini, et al.
Published: (2017-11-01)

Use of Human Chorionic Gonadotropin and Vaginal Progesterone Suppositories For Luteal Phase Support in Gonadotropin-Induced Cycles: A Comparative Study
by: Emel Ebru Özçimen, et al.
Published: (2006-04-01)

Update on management of ovarian hyperstimulation syndrome
by: Chin-Der Chen, et al.
Published: (2011-03-01)

Opportunities for ovarian reserve preservation in the treatment of oncological diseases
by: Juliia E. Dobrokhotova, et al.
Published: (2020-04-01)

Frozen thawed embryo transfer cycles; A comparison of pregnancy outcomes with and without prior pituitary suppression by GnRH agonists: An RCT
by: Alamtaj Samsami, et al.
Published: (2018-09-01)

Síndrome de hiperestimulación ovárica: clasificación, fisiopatología y manejo Ovarian hyperstimulation syndrome: classification, physiopathology and management
by: Jaime Saavedra Saavedra
Published: (2002-09-01)

Ovarian Hyperstimulation Syndrome (OHSS) Presented as Massive Hydrothorax
by: Pradip Kumar Saha, et al.
Published: (2013-12-01)

Arterial stiffness during controlled ovarian hyperstimulation and early pregnancy in women exposed to assisted reproduction
by: Emma von Wowern, et al.
Published: (2018-10-01)

The Risk of Hypercoagulability in Ovarian Hyperstimulation Syndrome
by: Damir Danolić, et al.
Published: (2015-01-01)

Effect of Endometrium Thickness on Clinical Outcomes in Luteal Phase Short-Acting GnRH-a Long Protocol and GnRH-Ant Protocol
by: Jie Zhang, et al.
Published: (2021-05-01)

Clinical outcomes of assisted reproductive technology treatment by using a self‐injection of recombinant human chorionic gonadotropin as the final maturation trigger
by: Koji Nakagawa, et al.
Published: (2018-04-01)